<DOC>
	<DOCNO>NCT00288080</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Hormone therapy use drug , leuprolide , goserelin , flutamide , bicalutamide , may fight prostate cancer lower amount androgen body make . Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , docetaxel prednisone , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give hormone therapy radiation therapy together chemotherapy effective give hormone therapy together radiation therapy treat prostate cancer . PURPOSE : This randomized phase III trial study hormone therapy radiation therapy follow docetaxel prednisone see well work compare hormone therapy radiation therapy treat patient localized prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Radiation Therapy Hormone Therapy Radiation Therapy Followed Docetaxel Prednisone Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare relative efficacy , term overall survival , combination androgen suppression radiotherapy versus androgen suppression radiotherapy follow docetaxel prednisone patient localize , high-risk prostate cancer . Secondary - Compare disease-free survival incidence adverse event patient treat regimen . - Compare biochemical control , local control , freedom distant metastases patient treat regimen . - Determine validity prostate-specific antigen ( PSA ) -defined endpoint surrogate overall survival patient treat regimen . - Compare time interval biochemical failure distant metastasis respect testosterone level patient treat regimen . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord risk group . - Arm I : Patients receive androgen suppression therapy comprise luteinizing hormone-releasing hormone ( LHRH ) agonist ( e.g. , leuprolide acetate , goserelin , buserelin , triptorelin ) oral antiandrogen ( i.e. , oral flutamide 3 time daily 2 month oral bicalutamide daily 2 month ) . Beginning week 8 , patient undergo radiotherapy 5 day week approximately 8 week . Antiandrogen therapy discontinue completion radiotherapy , LHRH agonist therapy continue 20 month . - Arm II : Patients receive androgen suppression therapy undergo radiotherapy arm I . Beginning 4 week completion radiotherapy , patient receive docetaxel IV 1 hour day 1 oral prednisone daily day 1-21 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients continue LHRH agonist therapy arm I . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 600 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer highrisk recurrence within past 180 day determine 1 follow combination ( risk group ) : Gleason score ≥ 9 , prostatespecific antigen ( PSA ) ≤ 150 ng/mL , T stage Gleason score 8 , PSA &lt; 20 ng/mL , stage ≥ T2 Gleason score 8 , PSA 20150 ng/mL , T stage Gleason score 7 , PSA 20150 ng/mL , T stage Clinically negative lymph node image ( pelvic CT scan pelvic MRI ) , nodal sampling , dissection within 90 day prior study entry Equivocal questionable lymph node ≤ 1.5 cm imaging allow Positive lymph node capromab pendetide ( ProstaScint^® ) scan correspond lymph node ≤ 1.5 cm CT scan MRI allow PSA ≤ 150 ng/mL Can obtain follow time point : 10day period prostate biopsy After initiation hormonal therapy Within 30 day discontinuation finasteride Within 90 day discontinuation dutasteride No distant metastasis physical exam bone scan Equivocal bone scan finding allow plain film negative PATIENT CHARACTERISTICS : Zubrod performance status 01 Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,800/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion intervention allow ) Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 1.5 time ULN Fertile patient must use effective contraception least 3 month completion study treatment No prior invasive malignancy , except nonmelanomatous skin cancer malignancy , unless diseasefree ≥ 3 year ( e.g. , carcinoma situ oral cavity bladder allow ) No unstable angina and/or congestive heart failure require hospitalization within past 6 month No transmural myocardial infarction within past 6 month No acute bacterial fungal infection require intravenous antibiotic No AIDS No prior allergic reaction study drug drug formulate polysorbate 80 No exist peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : At least 60 day since prior 5alpha reductase inhibitor ( e.g. , finasteride ) prostatic hypertrophy At least 90 day since prior testosterone Prior pharmacologic androgen ablation prostate cancer allow provide androgen ablation initiate 50 day prior study entry No prior radical prostatectomy , cryosurgery prostate cancer , bilateral orchiectomy No prior systemic chemotherapy prostate cancer Prior chemotherapy different cancer allow No prior radiotherapy , include brachytherapy , region prostate cancer would result overlap radiotherapy field Intensity modulate radiotherapy allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>